Inventor · disambiguated record
Tak W. Mak
Also filed as: MAK TAK · MAK TAK W · MAK TAK WAH
33 granted patents·9 pending applications·586 citations·filing 1980–2023
97Inventor score
Files withUNIV HEALTH NETWORK14ONTARIO CANCER INST11AMGEN CANADA INC5AMGEN INC5HOSPITAL FOR SPECIAL SURGERY2
Top patents by PatentIndex Score
42 records- 0197US5557032AKnockout miceONTARIO CANCER INST·Filed 1995·Granted Sep 17, 1996·104 cites·3 claims
- 0292US6468528B1Materials and methods to inhibit Hodgkin and Reed Sternberg cell growthAMGEN CANADA INC·Filed 2000·Granted Oct 22, 2002·67 cites·17 claims
- 0390US7708993B2Polypeptides involved in immune responseAMGEN INC·Filed 2006·Granted May 4, 2010·20 cites·9 claims
- 0490US5616491AKnockout miceONTARIO CANCER INST·Filed 1995·Granted Apr 1, 1997·58 cites·3 claims
- 0585US7312024B2Materials and methods to inhibit Hodgkin and Reed Sternberg cell growthAMGEN CANADA INC·Filed 2002·Granted Dec 25, 2007·26 cites·3 claims
- 0684US5907079AMSH2 disrupted mice develop lymphomasAMGEN CANADA INC·Filed 1996·Granted May 25, 1999·57 cites·15 claims
- 0779US5698765AMouse having a disrupted CD4 geneONTARIO CANCER INST·Filed 1995·Granted Dec 16, 1997·35 cites·5 claims
- 0876US7482325B2Downregulation of immune response by administering B7RP-2 fusion proteinAMGEN INC·Filed 2005·Granted Jan 27, 2009·4 cites·8 claims
- 0976US4713332AT cell specific CDNA cloneONTARIO CANCER INST·Filed 1984·Granted Dec 15, 1987·29 cites·24 claims
- 1075US5625122AMouse having a disrupted lck geneONTARIO CANCER INST·Filed 1993·Granted Apr 29, 1997·41 cites·7 claims
- 1173US5731490AMutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)ONTARIO CANCER INST·Filed 1995·Granted Mar 24, 1998·29 cites·6 claims
- 1270US2023390294A1Combination therapies for inhibition of ttk protein kinaseUNIV HEALTH NETWORK·Filed 2023·Application pending·0 cites
- 1369US9493561B2Antibodies to TosoUNIV HEALTH NETWORK·Filed 2014·Granted Nov 15, 2016·2 cites·5 claims
- 1468US10822388B2Methods and compositions for modulating toso activityUNIV HEALTH NETWORK·Filed 2017·Granted Nov 3, 2020·0 cites·3 claims
- 1568US4923799AT cell specific cDNA cloneONTARIO CANCER INST·Filed 1987·Granted May 8, 1990·27 cites·20 claims
- 1666US9321824B2Methods and compositions for modulating Toso activityUNIV HEALTH NETWORK·Filed 2014·Granted Apr 26, 2016·0 cites·6 claims
- 1766US8309083B2Polypeptides involved in immune responseYOSHINAGA STEVEN K·Filed 2010·Granted Nov 13, 2012·1 cites·5 claims
- 1865US9670265B2Methods and compositions for modulating toso activityUNIV HEALTH NETWORK·Filed 2014·Granted Jun 6, 2017·0 cites·9 claims
- 1965US9624289B2Methods and compositions for modulating Toso activityUNIV HEALTH NETWORK·Filed 2014·Granted Apr 18, 2017·0 cites·5 claims
- 2065US9132138B2Method for the treatment of multiple sclerosisCASI PHARMACEUTICALS INC·Filed 2013·Granted Sep 15, 2015·1 cites·27 claims
- 2164US11766437B2Combination therapies for inhibition of TTK protein kinaseUNIV HEALTH NETWORK·Filed 2018·Granted Sep 26, 2023·0 cites·13 claims
- 2262US9228006B2Methods and compositions for modulating Toso activityUNIV HEALTH NETWORK·Filed 2013·Granted Jan 5, 2016·0 cites·6 claims
- 2362US5714667AMice lacking expression of CTLA-4 receptorAMGEN CANADA INC·Filed 1995·Granted Feb 3, 1998·18 cites·6 claims
- 2461US10024844B2Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2HOSPITAL FOR SPECIAL SURGERY·Filed 2013·Granted Jul 17, 2018·1 cites·4 claims
- 2560US6664107B1CD45 disrupted nucleic acidONTARIO CANCER INST UNIVERSITY·Filed 1994·Granted Dec 16, 2003·19 cites·5 claims
- 2658US12109215B2Combination therapies for inhibition of polo-like kinase 4UNIV HEALTH NETWORK·Filed 2018·Granted Oct 8, 2024·0 cites·8 claims
- 2755US2008167264A1Materials and methods to inhibit hodgkin and reed sternberg cell growthAMGEN INC·Filed 2007·Application pending·0 cites
- 2852US2014004129A1Novel Polypeptides Involved in Immune ResponseAMGEN CANADA INC·Filed 2012·Application pending·0 cites
- 2950US5530178AMutant mouse lacking CD8 surface markerONTARIO CANCER INST·Filed 1993·Granted Jun 25, 1996·14 cites·4 claims
- 3047US2015250853A1Methods and compositions for modifying the immune responseUNIV HEALTH NETWORK·Filed 2015·Application pending·0 cites
- 3147US2010292302A1Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activityMAK TAK W·Filed 2008·Application pending·0 cites
- 3247US2015252434A1Methods and compositions for detection of targets involved in cancer metastasisUNIV HEALTH NETWORK·Filed 2015·Application pending·0 cites
- 3343US4366077ATemper rolling fluidsLYSAGHT AUSTRALIA LTD·Filed 1980·Granted Dec 28, 1982·9 cites·23 claims
- 3443US2003039999A1B7 related protein-2 molecules and uses thereofAMGEN INC·Filed 2002·Application pending·0 cites
- 3542US10533222B2Methods and compositions for detection of targets for autoimmune diseaseUNIV HEALTH NETWORK·Filed 2015·Granted Jan 14, 2020·0 cites·7 claims
- 3640US2018201676A1Methods and compositions for modulating lilr proteinsUNIV HEALTH NETWORK·Filed 2016·Application pending·0 cites
- 3738US5786152AMethods of inhibiting syp binding to a CTLA-4 receptorAMGEN INC·Filed 1996·Granted Jul 28, 1998·10 cites·14 claims
- 3837US5684222AMutant mouse having a disrupted TNFRp55ONTARIO CANCER INST·Filed 1994·Granted Nov 4, 1997·7 cites·7 claims
- 3935US5532158AInterleukin-2 receptor deficient mammalsONTARIO CANCER INST·Filed 1994·Granted Jul 2, 1996·6 cites·2 claims
- 4032US6552246B1Transgenic mice comprising CD45 knockoutUNIV HEALTH NETWORK·Filed 1995·Granted Apr 22, 2003·1 cites·4 claims
- 4132US2015241429A1Irhom2 inhibition for the treatment of complement mediated disordersHOSPITAL FOR SPECIAL SURGERY·Filed 2013·Application pending·0 cites
- 4230US5675059AMouse lacking the expression of interferon regulatory factor 2 (IRF-2)ONTARIO CANCER INST·Filed 1993·Granted Oct 7, 1997·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Tak W. Mak files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →